IGF1R and osteosarcoma: Additionally, a Phase 1/2 clinical trial (NCT03746431) targeting IGF1R-overexpressing solid tumors with a radioimmunotherapeutic agent ([225Ac]-FPI-1434) is ongoing, which could prove to be promising for osteosarcoma treatment.